



MARYLAND ACADEMY OF FAMILY PHYSICIANS

ABLE, RESPONSIVE FAMILY PHYSICIANS SERVING THEIR COMMUNITIES

References for Articles Appearing in the Spring, 2014 Edition of The Maryland Family Doctor Theme: Selected Topics in Cancer Management

MEETING THE CHALLENGES OF CANCER CARE

Joyce Evans, M.D.

¹ www.nytimes.com/2014/01/05/sunday-review/ why everyone seems to have cancer

¹ <http://www.who.int/mediacentre/facts/sheets>

¹ www.sciencetranslationalmedicine.org Vol 5 issue175) 6 March 2013

¹ <http://www.cancer.org/research/cancerfactsstatistics/index>

¹ <http://www.cancer.org/research/cancerfactsstatistics/index>

¹ <http://www.cancer.org>

¹ [Http://healthypeople.gov/2020](http://healthypeople.gov/2020)

¹ [http://cdc.gov/mmwr/62\(34\):685-683](http://cdc.gov/mmwr/62(34):685-683)

SHARED CARE FOR HEMATOLOGIC MALIGNANCY AND STEM CELL TRANSPLANT SURVIVORS

Amer Beitinjaneh, M.D., MPH

1. Bhatia S. Long-term complications of therapeutic exposures in childhood: Lessons learned from childhood cancer survivors. *Pediatrics*. 2012;130(6):1141-1143. doi: 10.1542/peds.2012-2884; 10.1542/peds.2012-2884.

2. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med*. 2006;355(15):1572-1582. doi: 10.1056/NEJMsa060185.


3. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort. *BMJ*. 2009;339:b4606. doi: 10.1136/bmj.b4606.

4. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. *Blood*. 2007;110(9):3463-3471. doi: 10.1182/blood-2006-10-054080.

5. Chow EJ, Friedman DL, Stovall M, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: A report from the childhood cancer survivor study. *Pediatr Blood Cancer*. 2009;53(3):432-437. doi: 10.1002/pbc.22082; 10.1002/pbc.22082.

6. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. *Expert Rev Hematol*. 2009;2(5):583-601. doi: 10.1586/ehm.09.48; 10.1586/ehm.09.48.

7. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: A practical approach to diagnosis and treatment. *Clin Chest Med.* 2004;25(1):189-201. doi: 10.1016/S0272-5231(03)00121-7.
8. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. *Hepatology.* 2010;51(4):1450-1460. doi: 10.1002/hep.23533; 10.1002/hep.23533.
9. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: Epidemiology, pathogenesis, and treatment. *J Am Soc Nephrol.* 2006;17(7):1995-2005. doi: 10.1681/ASN.2006020118.
10. Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. *Neurology.* 2003;60(5):842-848.
11. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. *Blood.* 2008;111(12):5515-5523. doi: 10.1182/blood-2007-10-117150; 10.1182/blood-2007-10-117150.
12. Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2011;17(3):300-308. doi: 10.1016/j.bbmt.2010.04.003; 10.1016/j.bbmt.2010.04.003.
13. Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: Report from the international consensus conference on clinical practice in cGVHD. *Clin Oral Investig.* 2011;15(2):127-139. doi: 10.1007/s00784-010-0450-6; 10.1007/s00784-010-0450-6.
14. Kim SK. Update on ocular graft versus host disease. *Curr Opin Ophthalmol.* 2006;17(4):344-348. doi: 10.1097/01.icu.0000233952.09595.d8.



Long term complications can affect all body systems resulting in considerable morbidity in cancer survivors.
Sadak, K. T. et al. *Nat. Rev. Urol.* doi:10.1038/nrurol.2012.218

WHAT'S NEW IN BREAST CANCER RESEARCH, DIAGNOSIS, AND TREATMENT

Sarah Ines Ramirez, M.D.

1. <http://www.cancer.net/cancer-types/breast-cancer>
2. <http://www.cdc.gov/nchs/fastats/lcod.htm>
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. *Lancet*. 2002;360:1347-1360.
4. International Agency for Research on Cancer Weight Control and Physical Activity 2002. Vol. 6 Lyon: International Agency for Research on Cancer; IARC Handbook on Cancer Prevention.
5. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. *Cancer Prev Res*. 2011; 4, 1021-9.
6. Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY, Duggan CR, Mason C, Imayama I, Kong A, Xiao L, Bain CE, Blackburn GL, Stanczyk FZ, McTiernan A. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. *Journal of Clinical Oncology*. 2012; 30(19):2314-2326.
7. Lisanti MP, Tsigos A, Pavlides S, Reeves KJ, Peiris-Pagès M, Chadwick AL, Sanchez-Alvarez R, Lamb R, Howell A, Martinez-Outschoorn UE, Sotgia F. JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: Connecting fibrosis, inflammation, and stemness for cancer prevention. *Cell Cycle*, 2014; 13 (4): 0
8. Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, Umetani M, Euhnus DM, Xie Y, Shaul PW. 27-hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. *Cell Reports*. 2013; 5: 637-645.
9. Cate SP, Gillego A, Chadha M, Rescigno J, Gliedman PR, Kats I, Boolbol SK. Does the Oncotype DCIS score impact treatment decisions. *J Clin Oncol*. 2013; supplement 26; abstract 91
10. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *J Natl Cancer Inst*. 2013; 105(10): 701-710.
11. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. *JAMA Intern Med*. 2013; 173(19):1830-1831.
12. Y. Li, Y. Li, T. Chen, A. S. Kuklina, P. Bernard, F. J. Esteva, H. Shen, M. Ferrari, Y. Hu. Circulating proteolytic products of carboxypeptidase n for early detection of breast cancer. *Clinical Chemistry*, 2014; v. 60, p 233-242.
13. Houston Methodist. "Early stages breast cancer could soon be diagnosed from blood samples." *ScienceDaily*. ScienceDaily, 14 November 2013.
14. Ramirez SI, Scholle M, Buckmaster J, Kowdley GC. 2012. Assessment of the accuracy of ultrasound compared to magnetic resonance imaging in the ability to detect metastatic breast cancer in the axilla. *Surgical Techniques Development*. 2013; 2:e4, 10-13.
15. <http://www.medicalnewstoday.com/articles/269693.php>

16. Munhoz AM, Montag E, Gemperli R. Current aspects of therapeutic reduction mammoplasty for immediate early breast cancer management: an update. *World J Clin Oncol.* 2014; 5(1): 1-18.

ONCOLOGIC EMERGENCIES & THE FAMILY PHYSICIAN

Caitlin Costello, M.D.

1. ¹Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. *Blood* 2001; 97:2998-3003.
2. ¹ Stewart AF. Clinical practice. Hypercalcemia associated with cancer. *N Engl J Med* 2005; 352:373-9.
3. ¹ Roodman GD. Biology of osteoclast activation in cancer. *J Clin Oncol* 2001; 19:3562-71.
4. ¹ Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious disease society of America. *Clin Infect Dis.* 2011;52(4):e56.
5. ¹ Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom's macroglobulinemia. *Oncologist* 2000; 5:63-7.
6. ¹ Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. *Eur J Cancer.* 1994; 30A(1):22.
7. ¹ Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical Characteristics and Evolving Etiology. *Medicine (Baltimore).* 2006;85(1):37.
8. ¹ Yellin A, Rosen A, Reichert N, Lieberman Y. Superior Vena Cava Syndrome. The Myth-The Facts. *Am Rev Respir Dis.* 1990; 141(5 Pt 1):1114.
9. ¹ Maisch B, Ristic A, Pankuweit S. Evaluation and Management of Pericardial Effusion in Patients with Neoplastic Disease. *Prog Cardiovasc Dis.* 2010;53(2):157.
10. ¹ Doellman D, Hadaway L, Bowe-Geddes LE, Franklin M, LeDonne J, Papke-O'Donnell L, Pettit J, Schulmeister L, Stranz M. Infiltration and Extravasation: Update on the Prevention and Management. *J Infus Nurs.* 2009 Jul;32(4):203-11.

UPDATE ON MALIGNANT MELANOMA

Marcia S. Driscoll, M.D.

1. Little EG, Eide MJ. Update on the current state of melanoma incidence. *Dermatol Clin* 2012;30:355-61.
2. Lin JS, Eder M, Weinman S, et al. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. *Ann Int Med* 2011;154:190-201.
3. Gandini S, Sera F, Cattaruzza M, et al. Meta-analysis of risk factors for cutaneous melanoma. II. sun exposure. *Eur J Cancer* 2005;41:45-60.
4. Gandini S, Sera F, Cattaruzza M, et al. Meta-analysis of risk factors for cutaneous melanoma. III. family history, actinic damage, and phenotypic factors. *Eur J Cancer* 2005;41:2040-2059.
5. Gandini S, Sera F, Cattaruzza M, et al. Meta-analysis of risk factors for cutaneous melanoma: I. common and atypical nevi. *Eur J Cancer* 2005;41:28-44.
6. Florell SR, Boucher KM, Garibotti G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. *J Clin Oncol* 2005;23:7168-7177.
7. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Res* 2006;66:9818-9828.
8. Leachman SA, Carucci J, Kohlman W, et al. Selection criteria for genetic assessment of patients with familial melanoma. *J Am Acad Dermatol* 2009;61:677.e1-14.

9. Scope A, Dusza SW, Halpern AC, et al. The “ugly duckling” sign: agreement between observers. *Arch Dermatol* 2008;144:58-64.
10. Roesch A, Burgdorf W, Stolz W, et al. Dermatoscopy of “dysplastic nevi”: a beacon in diagnostic darkness. *Eur J Dermatol* 2006;16:479-493.
11. Noor O 2nd, Nanda A, Rao BK. A dermoscopy survey to assess who is using it and why it is or is not being used. *Int J Dermatol* 2009;48:951-952.
12. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-723.
13. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507-2516.
14. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF-inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma [abstract]. *J Clin Oncol* 2012;30(Suppl 15): Abstract 8507.
15. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. *Eur J Cancer* 2013;49:1297-1304.
16. www.cancer.gov/cancer/topics/drug-info/fda-dabrafenib. Updated 1/16/14.

TESTICULAR AND PENILE CANCERS

Karl T. Rew, M.D.

Testicular Cancer

American Cancer Society. Testicular Cancer (Detailed Guide). Website: American Cancer Society, Learn About Cancer, Testicular Cancer. Available at

<http://www.cancer.org/acs/groups/cid/documents/webcontent/003142-pdf.pdf>. Published 2012. Updated 1/17/13.

Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. *CA-Cancer J Clin*. 2014;64(1):9–29. doi: 10.3322/caac.21208.

Shaw J. Diagnosis and Treatment of Testicular Cancer. *Am Fam Physician*. 2008;77(4):469-474

Tiemstra JD, Kapoor S. Evaluation of Scrotal Masses. *Am Fam Physician*. 2008 Nov 15;78(10):1165-1170.

US Preventive Services Task Force. Screening for Testicular Cancer, Reaffirmation Recommendation Statement. Website: USPSTF. Available at:

<http://www.uspreventiveservicestaskforce.org/uspstf10/testicular/testicuprs.htm>. Published April 2011.

Wampler SM, Llanes M. Common scrotal and testicular problems. *Prim Care*. 2010;37(3):613-626.

Penile Cancer

American Cancer Society. Penile Cancer (Detailed Guide). Website: American Cancer Society, Learn About Cancer, Penile Cancer. Available at

<http://www.cancer.org/acs/groups/cid/documents/webcontent/003132-pdf.pdf>. Updated 12/6/2013.

Brosman SA. Penile cancer. Medscape Reference. <http://emedicine.medscape.com/article/446554-overview#showall>. Accessed February 3, 2014.

Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep*. 2011;60(50):1705-8.

Larke NL, Thomas SL, dos Santos Silva I, Weiss HA. Male circumcision and penile cancer: a systematic review and meta-analysis. *Cancer Cause Control*. 2011;22(8):1097-110.

Pizzocaro G, Algaba F, Horenblas S, et al. EAU Penile Cancer Guidelines 2009. *Eur Urol*. 2010(57):1002-1012.

Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. *CA-Cancer J Clin*. 2014;64(1):9-29. doi: 10.3322/caac.21208.

Teichman JMH, Sea J, Thompson IM, Elston DM. Noninfectious Penile Lesions. *Am Fam Physician*. 2010;81(2):167-174.